Effects of Caffeine on Cerebral Blood Flow

Status Completed

Clinical Trial Summary

The goal of this clinical trial is to evaluate in clinically healthy young people if: - after caffeine ingestion, there are variations in blood velocity of the middle cerebral arteries (VMCA), - this variation is dependent on the administered dose. Transcranial Doppler ultrasonography was used to record blood VMCA in three groups of 15 clinically healthy young adults each - no caffeine, low caffeine (45 mg) and high caffeine group (120 mg). Transcranial Doppler ultrasonography provided simultaneous bilateral VMCA measurements while subjects performed functional tests (hyperventilation and hypoventilation orders) and three cognitive activities (Test 1, short-term remembering, Test 2, solving a vocabulary problem, and Test 3, solving a math problem) each in 31-second tests with 1-minute rest between them. Participants were assessed before and 30 minutes after caffeine ingestion.

Clinical Trial Description

Were used in the study, Capsules dosed with 45mg and 120 mg of anhydrous caffeine and flour capsules as a placebo. In the preparation of the capsules, a semi-automatic capsulator No. 0 (Capsunorm® by Tecnyfarma®) were used, colorless hard gelatin capsules No. 0 by Acopharma® and anhydrous caffeine (Biochem®, C.A.S. 58-08-2). Viasys Sonara transcranial Doppler unit and a 2 MHz probe were used to sample the middle cerebral artery at depths of 60 millimeters, using emission doppler pulsed performing spectral analysis in real time. Two probes (bilaterally) of 2MHz were placed at a depth between 55 and 60 mm, thus making it possible to analyse both middle cerebral arteries simultaneously. Each participant was asked not to ingest caffeine and exercise vigorously for at least 12 hours before the assessment. In the case of smokers, they were also asked not to smoke for at least 2 hours before the evaluation. The laboratory had medium luminosity, silent and controlled temperature (23º/24ºC). To avoid inter-observer errors, all examinations were performed by the same investigator who was not aware of what dose was/had been administered to the participant. Subjects were tested while seated in a reclining chair located in a dimly lit, sound-attenuated room and performed the activities with their eyes closed. ;

Study Design

Related Conditions & MeSH terms

Cardiovascular System

Clinical Trial Details

NCT number	NCT05866848
Study type	Interventional
Source	Escola Superior de Tecnologia da Saúde de Coimbra
Contact
Status	Completed
Phase	N/A
Start date	May 1, 2021
Completion date	June 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03697499` - Effects of Fish Oil in Alleviating Health Hazards Associated With Ozone Exposure	N/A
Active, not recruiting	`NCT04153539` - Acute Health Effects of Traffic-Related Air Pollution Exposure	N/A
Completed	`NCT04579497` - Temperature-dependent Changes in Cardiovascular Parameters During Warm Water Footbaths in Healthy Women	N/A
Active, not recruiting	`NCT05575752` - Acute Health Effects of High Temperature Exposure	N/A
Completed	`NCT02977390` - Passive Leg Raise Induced Stroke Volume Changes in Elderly Prior to Elective Surgery Measured by LiDCOplusTM	N/A
Not yet recruiting	`NCT06076629` - Acute Health Effects of Low Temperature Exposure	N/A
Completed	`NCT05289817` - Effects of Transcutaneous Electrical Stimulation on the Autonomous Nerve System in Healthy Young People	N/A
Completed	`NCT04209738` - Changes in Cardiovascular and Sleep Quality Parameters Under Eurythmy Therapy and Tai Chi in Comparison to Standard Care - A Substudy of the ENTAiER Trial
Recruiting	`NCT05727332` - Vascular Adaptations to Single-Sprint Training	Phase 2
Completed	`NCT02979327` - Cardiovascular Effects of Adderall in Healthy Adults.	Early Phase 1
Completed	`NCT01940822` - Cardiovascular Effects of Energy Drinks in Healthy Adults	N/A
Completed	`NCT03395977` - Uric Acid Effects on Endothelium and Oxydative Stress	N/A
Completed	`NCT03810118` - Fluid Challenge Infusion and Response	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.